Get the Stockscreener App
1.27
0.00%
0.00
Cabaletta Bio Inc stock is traded at $1.27, with a volume of 362.74K.
It is up +0.00% in the last 24 hours and down -23.49% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$1.27
Open:
$1.3
24h Volume:
362.74K
Relative Volume:
0.36
Market Cap:
$59.37M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-0.7651
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
+15.45%
1M Performance:
-23.49%
6M Performance:
-67.52%
1Y Performance:
-89.57%
1-Day Range:
$1.23
$1.31
1-Week Range:
$1.08
$1.39
52-Week Range:
$0.9857
$13.50
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.27 | 59.37M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
CABA’s Financial Health: Exploring Cabaletta Bio Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Is Cabaletta Bio Inc (CABA) a good investment opportunity? - uspostnews.com
American Superconductor Corp (AMSC) requires closer examination - uspostnews.com
Aehr Test Systems (AEHR) shows promising results - uspostnews.com
Wellington Management Group LLP Has $409,000 Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio Q1 EPS Estimate Increased by HC Wainwright - MarketBeat
William Blair Boosts Earnings Estimates for Cabaletta Bio - MarketBeat
William Blair Forecasts Cabaletta Bio Q1 Earnings - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $3.00 by Analysts at Wells Fargo & Company - MarketBeat
HC Wainwright Weighs in on Cabaletta Bio FY2029 Earnings - MarketBeat
Cantor Fitzgerald Weighs in on Cabaletta Bio FY2025 Earnings - MarketBeat
UBS Group Issues Pessimistic Forecast for Cabaletta Bio (NASDAQ:CABA) Stock Price - MarketBeat
Thrivent Financial for Lutherans Buys New Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio (NASDAQ:CABA) Posts Quarterly Earnings Results, Hits Expectations - MarketBeat
Q1 EPS Estimates for Cabaletta Bio Raised by HC Wainwright - Defense World
Cabaletta Bio (NASDAQ:CABA) Given Buy Rating at Guggenheim - MarketBeat
William Blair Increases Earnings Estimates for Cabaletta Bio - Defense World
Cabaletta Bio (NASDAQ:CABA) Issues Earnings Results, Meets Estimates - MarketBeat
Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from HC Wainwright - MarketBeat
William Blair Comments on Cabaletta Bio Q1 Earnings - Defense World
Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN
Analysts Offer Predictions for Cabaletta Bio FY2029 Earnings - Defense World
FY2025 EPS Forecast for Cabaletta Bio Raised by Analyst - Defense World
Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline By Investing.com - Investing.com South Africa
Kaskela Law LLC Announces Stockholder Investigation of Cabaletta Bio, Inc.CABA - ACCESS Newswire
Cabaletta Bio stock hits 52-week low at $1.15 amid sharp decline - Investing.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of “Buy” by Analysts - Defense World
Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat
Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio’s (CABA) “Buy” Rating Reaffirmed at Guggenheim - Defense World
Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo & Company Cuts Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00 - Defense World
Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com Australia
Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks
UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa
Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com
UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener
Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks
Cabaletta Bio: Strong Clinical Progress and Financial Stability Drive Buy Rating - TipRanks
Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada
Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com
Cabaletta Bio Reports Wider Q4 Results As R&D Expenses Rise - Nasdaq
BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Cabaletta Bio, Inc. SEC 10-K Report - TradingView
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):